These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 29853716)

  • 1. [ANMCO/ANCE/ARCA/GICR-IACPR intersociety consensus document: long-term antiplatelet therapy in patients with coronary artery disease].
    Gulizia MM; Colivicchi F; Abrignani MG; Ambrosetti M; Aspromonte N; Barile G; Caporale R; Casolo G; Chiuini E; Di Lenarda A; Faggiano P; Gabrielli D; Geraci G; La Manna AG; Maggioni AP; Marchese A; Massari FM; Mureddu GF; Musumeci G; Nardi F; Panno AV; Pedretti RFE; Piredda M; Pusineri E; Riccio C; Rossini R; Scotto Di Uccio F; Urbinati S; Varbella F; Zito GB; De Luca L
    G Ital Cardiol (Rome); 2018 May; 19(5):263-331. PubMed ID: 29853716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Consensus Document ANMCO/ANCE/ARCA/GICR-IACPR/GISE/SICOA: Long-term Antiplatelet Therapy in Patients with Coronary Artery Disease.
    Gulizia MM; Colivicchi F; Abrignani MG; Ambrosetti M; Aspromonte N; Barile G; Caporale R; Casolo G; Chiuini E; Di Lenarda A; Faggiano P; Gabrielli D; Geraci G; La Manna AG; Maggioni AP; Marchese A; Massari FM; Mureddu GF; Musumeci G; Nardi F; Panno AV; Pedretti RFE; Piredda M; Pusineri E; Riccio C; Rossini R; di Uccio FS; Urbinati S; Varbella F; Zito GB; De Luca L; ;
    Eur Heart J Suppl; 2018 May; 20(Suppl F):F1-F74. PubMed ID: 29867293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
    ; Bittl JA; Baber U; Bradley SM; Wijeysundera DN
    Circulation; 2016 Sep; 134(10):e156-78. PubMed ID: 27026019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strategies to Optimize Dual Antiplatelet Therapy After Coronary Artery Stenting in Acute Coronary Syndrome.
    Paravattil B; Elewa H
    J Cardiovasc Pharmacol Ther; 2017 Jul; 22(4):347-355. PubMed ID: 28587584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Guanxinning tablet for patients who switch from dual antiplatelet therapy to aspirin alone after percutaneous coronary intervention: study protocol for a cluster randomized controlled trial.
    Li J; Ju J; Chen Z; Liu J; Lu F; Gao R; Xu H
    Trials; 2018 Feb; 19(1):93. PubMed ID: 29415754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: rationale and design of the REDUCE trial.
    Camaro C; Damen SA; Brouwer MA; Kedhi E; Lee SW; Verdoia M; Barbieri L; Rognoni A; van T Hof AW; Ligtenberg E; de Boer MJ; Suryapranata H; De Luca G
    Am Heart J; 2016 Aug; 178():37-44. PubMed ID: 27502850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bleeding versus thrombosis: role of short DAPT in complex lesions.
    Calcagno S; Lucisano L; Mancone M; Cavallo E; Pennacchi M; Stio RE; Sardella G
    Minerva Cardioangiol; 2015 Dec; 63(6):533-46. PubMed ID: 26334115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Shorter (≤6 months) versus longer (≥12 months) duration dual antiplatelet therapy after drug eluting stents: a meta-analysis of randomized clinical trials.
    Pandit A; Giri S; Hakim FA; Fortuin FD
    Catheter Cardiovasc Interv; 2015 Jan; 85(1):34-40. PubMed ID: 24753084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term antiplatelet therapy following myocardial infarction: implications of PEGASUS-TIMI 54.
    Parker WA; Storey RF
    Heart; 2016 May; 102(10):783-9. PubMed ID: 26857211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal duration of dual antiplatelet therapy after PCI: integrating procedural complexity, bleeding risk and the acuteness of clinical presentation.
    Chen H; Power D; Giustino G
    Expert Rev Cardiovasc Ther; 2018 Oct; 16(10):735-748. PubMed ID: 30221557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toward Brief Dual Antiplatelet Therapy and P2Y12 Inhibitors for Monotherapy After PCI.
    Ayoub A; Ayinapudi K; Al-Ogaili A; Panhwar MS; Dakkak W; LeJemtel T
    Am J Cardiovasc Drugs; 2021 Mar; 21(2):153-163. PubMed ID: 32780215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term outcomes in patients with acute coronary syndromes related to prolonging dual antiplatelet therapy more than 12 months after coronary stenting.
    Wimmer NJ; Dufour AB; Cho K; Gagnon DR; Quach L; Ly S; Do JM; Ostrowski S; Michael Gaziano J; Faxon DP; Kinlay S
    Catheter Cardiovasc Interv; 2017 Jun; 89(7):1176-1184. PubMed ID: 27860195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of aspirin intolerance in patients undergoing percutaneous coronary intervention. The role of mono-antiplatelet therapy: a retrospective, multicenter, study.
    Bianco M; Gravinese C; Cerrato E; Nuñez-Gil I; Destefanis P; Luciano A; Biscaglia S; Quadri G; Tizzani E; Corleto A; Giolitto S; Lo Savio L; Campo G; Varbella F; Pozzi R
    Minerva Cardioangiol; 2019 Apr; 67(2):94-101. PubMed ID: 30895761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Sex on 2-Year Clinical Outcomes in Patients Treated With 6-Month or 24-Month Dual-Antiplatelet Therapy Duration: A Pre-Specified Analysis From the PRODIGY Trial.
    Gargiulo G; Ariotti S; Santucci A; Piccolo R; Baldo A; Franzone A; Magnani G; Marino M; Esposito G; Windecker S; Valgimigli M
    JACC Cardiovasc Interv; 2016 Sep; 9(17):1780-9. PubMed ID: 27544007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia) trial.
    Costa F; Vranckx P; Leonardi S; Moscarella E; Ando G; Calabro P; Oreto G; Zijlstra F; Valgimigli M
    Eur Heart J; 2015 May; 36(20):1242-51. PubMed ID: 25718355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence, predictors, and outcomes of DAPT disruption due to non-compliance vs. bleeding after PCI: insights from the PARIS Registry.
    Moalem K; Baber U; Chandrasekhar J; Claessen BE; Sartori S; Aquino M; Dangas G; Iakovou I; Colombo A; Kini A; Gibson M; Krucoff M; Chieffo A; Moliterno D; Witzenbichler B; Pocock S; Mehran R
    Clin Res Cardiol; 2019 Jun; 108(6):643-650. PubMed ID: 30607496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meta-Analysis of Duration of Dual Antiplatelet Therapy in Acute Coronary Syndrome Treated With Coronary Stenting.
    Knijnik L; Fernandes M; Rivera M; Cardoso R; Goyal A; Liberman H; Sperling LS; McDaniel MC
    Am J Cardiol; 2021 Jul; 151():25-29. PubMed ID: 34049672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of Early Adverse Events After Clopidogrel Discontinuation in Patients Undergoing Short-Term Dual Antiplatelet Therapy: An Individual Participant Data Analysis.
    Piccolo R; Feres F; Abizaid A; Gilard M; Morice MC; Hong MK; Kim HS; Colombo A; Bhatt DL; Palmerini T; Stone GW; Windecker S; Valgimigli M
    JACC Cardiovasc Interv; 2017 Aug; 10(16):1621-1630. PubMed ID: 28838471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence, Patterns, and Associations Between Dual-Antiplatelet Therapy Cessation and Risk for Adverse Events Among Patients With and Without Diabetes Mellitus Receiving Drug-Eluting Stents: Results From the PARIS Registry.
    Faggioni M; Baber U; Sartori S; Giustino G; Cohen DJ; Henry TD; Farhan S; Ariti C; Dangas G; Gibson M; Giacoppo D; Krucoff MW; Aquino M; Chandrasekhar J; Moliterno DJ; Colombo A; Vogel B; Chieffo A; Kini AS; Witzenbichler B; Weisz G; Steg PG; Pocock S; Mehran R
    JACC Cardiovasc Interv; 2017 Apr; 10(7):645-654. PubMed ID: 28330641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent.
    Valgimigli M; Cao D; Makkar RR; Bangalore S; Bhatt DL; Angiolillo DJ; Saito S; Ge J; Neumann FJ; Hermiller J; Picon H; Toelg R; Maksoud A; Chehab BM; Wang LJ; Wang J; Mehran R
    Am Heart J; 2021 Jan; 231():147-156. PubMed ID: 33031789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.